DE69940521D1 - Retrovirales genübertragungssystem und entsprechendes verwendungverfahren - Google Patents

Retrovirales genübertragungssystem und entsprechendes verwendungverfahren

Info

Publication number
DE69940521D1
DE69940521D1 DE69940521T DE69940521T DE69940521D1 DE 69940521 D1 DE69940521 D1 DE 69940521D1 DE 69940521 T DE69940521 T DE 69940521T DE 69940521 T DE69940521 T DE 69940521T DE 69940521 D1 DE69940521 D1 DE 69940521D1
Authority
DE
Germany
Prior art keywords
retroviral
transmission system
use method
corresponding use
tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69940521T
Other languages
English (en)
Inventor
Nori Kasahara
Christopher Logg
W French Andersen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southern California USC
Original Assignee
University of Southern California USC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Southern California USC filed Critical University of Southern California USC
Application granted granted Critical
Publication of DE69940521D1 publication Critical patent/DE69940521D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/854—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/80—Vectors comprising a special translation-regulating system from vertebrates
    • C12N2840/85—Vectors comprising a special translation-regulating system from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Radiation-Therapy Devices (AREA)
  • Vehicle Body Suspensions (AREA)
DE69940521T 1998-10-01 1999-10-01 Retrovirales genübertragungssystem und entsprechendes verwendungverfahren Expired - Lifetime DE69940521D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10293398P 1998-10-01 1998-10-01
PCT/US1999/023016 WO2000018240A1 (en) 1998-10-01 1999-10-01 Gene delivery system and methods of use

Publications (1)

Publication Number Publication Date
DE69940521D1 true DE69940521D1 (de) 2009-04-16

Family

ID=22292475

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69940521T Expired - Lifetime DE69940521D1 (de) 1998-10-01 1999-10-01 Retrovirales genübertragungssystem und entsprechendes verwendungverfahren

Country Status (9)

Country Link
US (4) US6410313B1 (de)
EP (3) EP1932426A1 (de)
AT (1) ATE424114T1 (de)
AU (1) AU1441900A (de)
CA (1) CA2346931C (de)
DE (1) DE69940521D1 (de)
DK (1) DK1115290T3 (de)
ES (1) ES2323744T3 (de)
WO (1) WO2000018240A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000018240A1 (en) 1998-10-01 2000-04-06 University Of Southern California Gene delivery system and methods of use
US6899871B2 (en) * 1998-10-01 2005-05-31 University Of Southern California Gene delivery system and methods of use
AU4559800A (en) * 1999-04-29 2000-11-17 Aarhus Universitet Expression of heterologous genes from an ires translational cassette in retroviral vectors
US6762031B2 (en) 2000-06-16 2004-07-13 University Of Medicine And Dentistry Of New Jersey Targeting viral vectors to specific cells
US7575924B2 (en) 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
ATE527347T1 (de) 2001-08-02 2011-10-15 Inst Clayton De La Rech Verfahren und zusammensetzungen im zusammenhang mit verbesserten lentivirusvektor- produktionssystemen
NZ532060A (en) * 2001-10-02 2005-11-25 Inst Clayton De La Rech Methods and compositions relating to restricted expression lentiviral vectors and their applications
CN100398649C (zh) * 2002-05-31 2008-07-02 浙江养生堂天然药物研究所有限公司 一种人白血病相关逆转录病毒基因组核酸序列及其应用
US7018835B2 (en) * 2002-08-20 2006-03-28 David Michael Hone Recombinant double-stranded RNA phage, and use of the same
US7897384B2 (en) * 2003-09-08 2011-03-01 Ethicon, Inc. Chondrocyte therapeutic delivery system
US7927599B2 (en) 2003-09-08 2011-04-19 Ethicon, Inc. Chondrocyte therapeutic delivery system
US8257963B2 (en) 2007-06-01 2012-09-04 Depuy Mitek, Inc. Chondrocyte container and method of use
JP2008521405A (ja) * 2004-11-24 2008-06-26 ナノヴェクター・リミテッド ウイルスベクター
MX337213B (es) 2008-06-30 2016-02-17 Tocagen Inc Formulaciones de 5-fluorocitosina y usos de las mismas.
JP5684130B2 (ja) * 2008-09-26 2015-03-11 トカジェン インコーポレーテッド 組換えベクター
US8829173B2 (en) 2008-09-26 2014-09-09 Tocagen Inc. Recombinant vectors
US20100183558A1 (en) 2008-10-17 2010-07-22 Zhennan Lai Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules
ES2718546T3 (es) * 2009-06-17 2019-07-02 Tocagen Inc Células productoras para vectores retrovirales de replicación competente
CA2816570A1 (en) 2010-10-31 2012-05-03 Tocagen Inc. Enhanced cancer treatment and monitoring using recombinant vectors
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
EP2586461A1 (de) 2011-10-27 2013-05-01 Christopher L. Parks Von einem eingehüllten Virus abgeleitete Virenpartikel
US9347065B2 (en) 2012-03-29 2016-05-24 International Aids Vaccine Initiative Methods to improve vector expression and genetic stability
JP6419706B2 (ja) * 2012-10-25 2018-11-07 トカジェン インコーポレーテッド ミニプロモーターカセットを含むレトロウイルスベクター
US9642921B2 (en) 2012-12-20 2017-05-09 Tocagen Inc. Cancer combination therapy and recombinant vectors
US20160175388A1 (en) 2013-06-15 2016-06-23 Tocagen Inc. Immunosuppressive components associated with retroviral replicating vectors
WO2015148683A1 (en) * 2014-03-26 2015-10-01 Tocagen Inc. A retroviral vector having immune-stimulating activity
EP3319631A4 (de) 2015-07-08 2019-01-09 American Gene Technologies International Inc. Hiv-vorimmunisierung und immuntherapie
US11279949B2 (en) 2015-09-04 2022-03-22 Denovo Biopharma Llc Recombinant vectors comprising 2A peptide
US10137144B2 (en) 2016-01-15 2018-11-27 American Gene Technologies International Inc. Methods and compositions for the activation of gamma-delta T-cells
IL310925A (en) 2016-01-15 2024-04-01 American Gene Tech Int Inc Methods and preparations for activating GAMMA-DELTA T cells
EP3413926A4 (de) 2016-02-08 2019-10-09 American Gene Technologies International, Inc. Hiv-impfung und immuntherapie
EP3426777B1 (de) 2016-03-09 2022-02-16 American Gene Technologies International Inc. Kombinationsvektoren und verfahren zur behandlung von krebs
WO2017213697A1 (en) * 2016-06-08 2017-12-14 American Gene Technologies International Inc. Non-integrating viral delivery system and methods related thereto
JP6971492B2 (ja) 2016-07-08 2021-11-24 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド Ｈｉｖ予備免疫化および免疫療法
US11583562B2 (en) 2016-07-21 2023-02-21 American Gene Technologies International Inc. Viral vectors for treating Parkinson's disease
US11820999B2 (en) 2017-04-03 2023-11-21 American Gene Technologies International Inc. Compositions and methods for treating phenylketonuria

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4405712A (en) 1981-07-01 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services LTR-Vectors
US4650764A (en) 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
US5997859A (en) * 1988-03-21 1999-12-07 Chiron Corporation Method for treating a metastatic carcinoma using a conditionally lethal gene
US5716826A (en) * 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
US6133029A (en) * 1988-03-21 2000-10-17 Chiron Corporation Replication defective viral vectors for infecting human cells
DE68921034D1 (de) * 1988-09-27 1995-03-23 Dana Farber Cancer Inst Inc Vektor, der ein replikationskompetentes HIV-I-Provirus und ein heterologes Gen enthält.
US5674486A (en) * 1991-06-25 1997-10-07 San Diego Regional Cancer Center Cancer immunotherapy with carrier cells
WO1993003143A1 (en) 1991-08-07 1993-02-18 Anderson W French Retroviral vectors containing internal ribosome entry sites
WO1993010218A1 (en) * 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
AU688292B2 (en) * 1992-11-09 1998-03-12 United States Government as represented by the Department of Health and Human Services, The Targetable vector particles
US5770428A (en) * 1993-02-17 1998-06-23 Wisconsin Alumni Research Foundation Chimeric retrovial expression vectors and particles containing a simple retroviral long terminal repeat, BLV or HIV coding regions and cis-acting regulatory sequences, and an RNA translational enhancer with internal ribsome entry site
JPH08511156A (ja) * 1993-04-06 1996-11-26 アメリカ合衆国 テナガザル白血球ウイルスベースのレトロウイルスベクター
FR2716459B1 (fr) * 1994-02-22 1996-05-10 Univ Paris Curie Système hôte-vecteur utilisable en thérapie génique.
US5585096A (en) * 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
US20030157070A1 (en) * 1994-12-30 2003-08-21 Jolly Douglas J. High efficiency ex vivo transduction of cells by high titer recombinant retroviral preparations
US6117681A (en) * 1995-03-29 2000-09-12 Bavarian Nordic Research Inst. A/S Pseudotyped retroviral particles
US20030026789A1 (en) * 1995-05-03 2003-02-06 Richard J. Gregory Gene therapy using replication competent targeted adenoviral vectors
GB9604354D0 (en) * 1996-02-29 1996-05-01 Isis Innovation Targeting adapters
US6025192A (en) * 1996-09-20 2000-02-15 Cold Spring Harbor Laboratory Modified retroviral vectors
US6248721B1 (en) * 1997-04-09 2001-06-19 Lung-Ji Chang Method of using mouse model for evaluation of HIV vaccines
US6207455B1 (en) * 1997-05-01 2001-03-27 Lung-Ji Chang Lentiviral vectors
AU1334999A (en) 1997-10-20 1999-05-10 Universita Degli Studi Di Padova A packaging cell line producing siv-pseudotyped mlv
FR2773561A1 (fr) 1998-01-15 1999-07-16 Centre Nat Rech Scient Utilisation d'une sequence riche en proline pour augmenter le caractere fusogenique d'enveloppes de retrovirus
EP1076714A1 (de) * 1998-04-29 2001-02-21 Oklahoma Medical Research Foundation Herstellung von retrovirale verpackungszellen aus adenoviraler und retroviraler vektoren
US6291214B1 (en) * 1998-05-11 2001-09-18 Glaxo Wellcome Inc. System for generating recombinant viruses
FR2778670B1 (fr) * 1998-05-18 2002-12-13 Rhone Poulenc Rorer Sa Methodes et compositions pour la production de particules virales
AU4089899A (en) * 1998-05-20 1999-12-06 University Of Tennessee Research Corporation, The Stable envelope proteins for retroviral, viral and liposome vectors and use in gene and drug therapy
US6322969B1 (en) * 1998-05-27 2001-11-27 The Regents Of The University Of California Method for preparing permuted, chimeric nucleic acid libraries
US6264940B1 (en) * 1998-08-05 2001-07-24 The Research Foundation Of State University Of New York Recombinant poliovirus for the treatment of cancer
US6899871B2 (en) * 1998-10-01 2005-05-31 University Of Southern California Gene delivery system and methods of use
WO2000018240A1 (en) * 1998-10-01 2000-04-06 University Of Southern California Gene delivery system and methods of use
US6576463B1 (en) * 1999-01-15 2003-06-10 The Regents Of The University Of California Hybrid vectors for gene therapy
AU4559800A (en) * 1999-04-29 2000-11-17 Aarhus Universitet Expression of heterologous genes from an ires translational cassette in retroviral vectors
EP1059357A1 (de) * 1999-06-09 2000-12-13 Universite Pierre Et Marie Curie Paris Vi Replizierende oder 'semi-replizierende' retrovirale Konstrukte, ihre Herstellung und Verwendungen für den Gentransfer
EP1059356B1 (de) 1999-06-09 2005-11-02 Universite Pierre Et Marie Curie Paris Vi Replizierende retrovirale Konstrukte, ihre Herstellung und Verwendungen für den Gentransfer
US8163893B2 (en) 2006-02-15 2012-04-24 The Regents Of The University Of Caifornia Pseudotyped retroviral vectors and methods of use thereof
WO2001040488A1 (en) * 1999-11-30 2001-06-07 Novartis Ag Increased transgene expression in retroviral vectors having scaffold attachment region
US6692736B2 (en) * 2000-03-24 2004-02-17 Cell Genesys, Inc. Cell-specific adenovirus vectors comprising an internal ribosome entry site
WO2002022663A2 (en) * 2000-09-18 2002-03-21 Maxygen, Inc. Stress resistant retroviruses
WO2002042482A2 (en) * 2000-11-27 2002-05-30 Chiron Corporation Functional lentiviral vector from an mlv-based backbone
WO2002061104A2 (en) * 2001-01-30 2002-08-08 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Hybrid adenoviral vector
DE10111433A1 (de) * 2001-03-09 2002-09-19 Bundesrepublik Deutschland Let Replikationskompetente molekulare Klone von porcinem endogenem Retrovirus der Klasse A und Klasse B,abgeleitet von Schweine- und humanen Zellen
JP2004532039A (ja) * 2001-03-26 2004-10-21 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ ヘルパー依存性アデノウイルスベクター系およびその系の使用方法
US7211247B2 (en) * 2001-04-09 2007-05-01 University Of Southern California Lentivirus vectors for gene transfer to alveolar epithelial cells
JP2002335965A (ja) * 2001-05-14 2002-11-26 Japan Science & Technology Corp 細胞特異的発現複製ベクター
DE10143237A1 (de) * 2001-09-04 2003-03-20 Icon Genetics Ag Herstellung künstlicher interner ribosomaler Eingangsstellenelemente (Ires-Elemente)
FR2832424B1 (fr) * 2001-11-20 2004-09-24 Genethon Iii Plasmide chimere comprenant un genome retroviral replicatif et utilisations
AU2003206815A2 (en) * 2002-02-01 2003-09-02 Transgene S.A. Adenoviral vectors for modulating the cellular activities associated with PODs
DE60328491D1 (de) * 2002-05-17 2009-09-03 Retrovec A P S Gereinigtes hüllprotein eines retrovirus, dafür kodierende nukleinsäuren, vektoren und deren verwendung
WO2005118802A2 (en) * 2004-06-03 2005-12-15 The Regents Of The University Of California Targeting pseudotyped retroviral vectors
US20070003522A1 (en) * 2004-07-08 2007-01-04 Albritton Lorraine M Methods and compositions for improved retroviral gene and drug delivery
JP2008521405A (ja) * 2004-11-24 2008-06-26 ナノヴェクター・リミテッド ウイルスベクター
EP2004677A2 (de) 2006-03-17 2008-12-24 Aarhus Universitet Chimäre virale hüllen
WO2008151633A2 (en) 2007-06-15 2008-12-18 Skau Aps Vectors for vaccines against lentivirus infections
MX337213B (es) 2008-06-30 2016-02-17 Tocagen Inc Formulaciones de 5-fluorocitosina y usos de las mismas.
JP5684130B2 (ja) 2008-09-26 2015-03-11 トカジェン インコーポレーテッド 組換えベクター

Also Published As

Publication number Publication date
CA2346931C (en) 2011-11-29
EP2386646A1 (de) 2011-11-16
AU1441900A (en) 2000-04-17
ES2323744T3 (es) 2009-07-23
EP1115290B1 (de) 2009-03-04
US20020127697A1 (en) 2002-09-12
DK1115290T3 (da) 2009-06-22
ATE424114T1 (de) 2009-03-15
EP1932426A1 (de) 2008-06-18
WO2000018240A1 (en) 2000-04-06
US6410313B1 (en) 2002-06-25
US20120052554A1 (en) 2012-03-01
US8652460B2 (en) 2014-02-18
EP1115290A1 (de) 2001-07-18
CA2346931A1 (en) 2000-04-06
US8741279B2 (en) 2014-06-03
EP2386646B1 (de) 2016-12-21
US20140234958A1 (en) 2014-08-21
EP1115290A4 (de) 2002-12-04

Similar Documents

Publication Publication Date Title
DE69940521D1 (de) Retrovirales genübertragungssystem und entsprechendes verwendungverfahren
WO2003060101A3 (en) Gene delivery system and methods of use
DE59800697D1 (de) Feuerfester werkstoff auf basis chromkorund, chromkorund-stein sowie verwendung des steins
BRPI9912663B1 (pt) vacina contra cáncer e polipeptìdeo.
ATE222956T1 (de) Hitzebeständige xylanasen
ES540629A0 (es) Un sistema para el control de desvio durante el funcionamiento de un ordenador en una modalidad de canalizacion.
NO2013009I1 (no) Alipogen tiparvovec
NL187785C (nl) Chirurgische kraminrichting.
DE3860523D1 (de) Biegbarer schlauch mit zueinander parallelen, ringfoermigen wellen und axialabstuetzung.
NO964628L (no) DNA-sekvenser
GB2351290A (en) Retroviral delivery sytem
FI973309A0 (fi) Menetelmä yhdistelmä-DNA-adenovirusgenomin valmistamiseksi
DE69838810D1 (de) Gen von alteromonas
DE69839765D1 (de) Lage-1 tumor-assozierte nukleinsäuren
NO864154D0 (no) Katalysatorpreparat, samt fremgangsmaate for dets fremstilling.
FI964784A (fi) Yhdistelmä-DNA-viruksia, valmistus ja käyttö geeniterapiassa
FI884556A0 (fi) Rekombinantplasmid-dna ppr-ifn 1-13, som kodas foer syntes av maenniskans fibroblast- 1-interferon, foerfarande foer framstaellning daerav och e.coli innehaollande detta.
SE8602945L (sv) Kopplingsmedel for termoplaster och oorganiska armeringsmedel
DE69938427D1 (de) Tes gen und dessen verwendung
ES284631Y (es) Quemador autovaporizador universal, especialmente para 24000kcal-h. perfeccionado
COOK BLOCKLEYS' CLAY PAVIORS- THE TOTAL CONCEPT.
AP9700991A0 (en) Toxins from the wasp bracon hebetor.
ATE348109T1 (de) Das gen prv-1 und dessen verwendung
ATE244309T1 (de) Verfahren zur herstellung und identifizierung von neuen hydrolasen mit verbesserten eigenschaften
DK161087D0 (da) Afgivelseskobling og afgivelsesfremgangsmaade til afgivelse af koefficienter.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition